Final Program and Oral Abstracts [International Conference on AIDS (8th: 1992: Amsterdam, Netherlands)]

WEDNESDAY, 22 JULY 1992 09.45-11.15

SESSIONS

SESSION 106
Wednesday, 22 July 1992
Time: 09.45-11.15
Lecture room: B1
Session title: NEW ANTIRETROVIRALS: REVERSE
TRANSCRIPTASE INHIBITORS
Oral Abstract
Chairperson: Anthony Pinching (UNITED KINGDOM)

10.35
A PHASE I MULTIPLE DOSE STUDY OF U-87, 201 E, A WeB 1015
NON-NUCLEOSIDE RT INHIBITOR, IN NORMAL
HEALTHY MALES
Cox, Steven R.*; Batts, D.H.*; Dietz, A.J.*; Hanover,
C.*; Peel, B.G.*; Elfring, G.L.*; Staton, B.A.*; *The
Upjohn Company; Kalamazoo; UNITED STATES
10.45
DISCUSSANT
Corey, Lawrence; University of Washington; UNITED
STATES

09.45
ANTI-VIRAL EFFECTS OF STAVUDINE (d4T) THERAPY
Anderson, Robert*; Meyer, W.**; Balch, F.*; Brown,
M.*; Ramirez-Ronda, C.***; Schwartz, R.****;
Petersen, E.*****; *Bristol-Myers Squibb Co;
Wallingford; UNITED STATES; **Maryland Medical
Laboratory; Baltimore;***University of Puerto Rico;
San Juan; PUERTO RICO; ****Investment Research
Assoc.; Ft Myers; *****University of Arizona; Tuscon
09.55
STAVUDINE (d4T) A PROMISING ANTI-RETROVIRAL
AGENT
Dunkle, Lisa*; Anderson, R.*; McLaren, C.*; Cross,
A.*; Brown, M.*; Gugliotti, R.O.; Kaul, S.*; Et AI.;
*Bristol-Myers Squibb Co.; Wallingford; UNITED
STATES

WeB 1010

NOTES

WeB 1011

10.05
EARLY MARKERS OF HEMATOLOGIC TOXICITY WITH WeB 1012
FLT THERAPY
Barditch-Crovo, Patricia A.*; Ganes, D.*; Duncanson,
F.*; Van der Horst, C.*; Polsky, B.*; Petty, B.*;
Faulkner, D.*; Et AI.; *Johns Hopkins University;
Baltimore; UNITED STATES

10.15
SAFETY AND RELATIVE ANTIRETROVIRAL ACTIVITY
OF L697, L661 VERSUS ZIDOVUDINE IN HIV-1
INFECTED PATIENTS
Saag, Michael S.*; Douglas, J.*; Lapidus, W.*;
DeLoach, L.*; Maples, V.*; Laskin, O.**; Massari, F.**;
Et AI.; *University of Alabama; Birmingham; UNITED
STATES; **Merck Sharp & Dohme Research Lab.;
West Point
10.25
A PHASE I/Il STUDY OF 3TC IN HIV POSITIVE,
ASYMPTOMATIC OR MILD ARC PATIENTS
Van Leeuwen, Remko*; Boucher, C.*; Katlama, C.**;
Ingrand, D.**; Kitchen, V.***; Weber, J.***; McDade,
H.****; *National AIDS Therapy Evaluation Centre,
Academical Medical Center; Amsterdam;
NETHERLANDS; **Hopital Pitie-Salpetriere; Paris;
FRANCE; ***St. Mary's Hospital, London; UNITED
KINGDOM; ****Glaxo Group Research LTD; Greenford

WeB 1013
WeB 1014

160